iPS Cells & Regenerative Medicine Weekly Report May 7, 2026

Sana Biotechnology to Announce Q1 Financial Results and Hypoimmune Cell Therapy Pipeline Progress at June Investor Conferences

DelveInsight Reports Robust Parkinson’s Disease Pipeline: Over 240 Therapies in Clinical and Preclinical Development

Japan Reinforces LMO Safety Regulations for Advanced Biotech Research and Regenerative Medicine

DelveInsight: 180+ Companies Propel CAR-T Innovation, Forging a New Era in Cell Therapy

Kelonia Therapeutics’ BCMA-Targeted In Vivo CAR T Therapy KLN-1010 Shows Promise for Multiple Myeloma with Updated Phase 1 ASCO Data

Voyager Therapeutics Receives FDA IND Clearance for VY1706, First Tau-Targeted Gene Therapy, to Begin Alzheimer’s Disease Phase 1 Trial

BlueRock Therapeutics Initiates Patient Enrollment for Parkinson’s Disease iPSC-Derived Cell Therapy exPDite-2 Phase 3 Trial; Long-Term Follow-Up Data Imminent

CRISPR Therapeutics Demonstrates Future Potential with Casgevy Approval, Leading Gene-Editing Market Through Pipeline Diversification